Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, and that is roughly 9.11 % above the present share price of $76.07.
Cherny expects CVS Health Corp to submit earnings per share (EPS) of $0.93 for the very first quarter of 2021.
The analysts price targets range from a high of hundred one dolars to a low of $61.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is $99.57 billion.
According to TipRanks.com, Merrill Lynch analyst Michael Cherny is presently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The retail or Long Term Care segment includes offering of prescription medications and assortment of general merchandise.
The Health Care Benefits segment offers quite traditional, voluntary and consumer-directed health insurance products as well as related services, including medical, pharmacy, dental, behavioural health, healthcare control capabilities. The Corporate segment involves in offering administrative services as well as management. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.